Norway's Aker BioMarine Q2 revenue rises on strength in human health ingredients segment

Aker Biomarine ASA

10/07/2026 06:11

Overview
Norway krill-derived health ingredient supplier's Q2 revenue rose 5% yr/yr
Adjusted EBITDA for Q2 fell 4% yr/yr
Human Health Ingredients segment revenue up 17% yr/yr, driven by krill oil sales growth

Outlook
Human Health Ingredients segment expects continued YoY growth and improved profits
Consumer Health Products segment expects revenues to return to modest growth
Company is exploring strategic alternatives for Human Health Ingredients unit, targeting a transaction in 2026

Result Drivers
KRILL OIL VOLUMES - Human Health Ingredients growth was driven mainly by solid krill oil volume growth and a higher share of capsulated oil
HIGHER SG&A - EBITDA margin in Human Health Ingredients was slightly below last year due to increased sales and marketing investments
RETAIL WEAKNESS & MARKETING REPOSITIONING - Consumer Health Products revenue declined due to lower sales through key US retail chains and ongoing marketing repositioning at Epion

Company press release: ID:nObifZTw1a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$57.90 mln
$60 mln (1 Analyst)
Q2 Adjusted EBITDA
Miss
$12.90 mln
$14 mln (2 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the fishing & farming peer group is "buy."
Wall Street's median 12-month price target for Aker Biomarine ASA is NOK120.00, about 20% above its July 9 closing price of NOK100.00
The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 32 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)